Riskpilot← Back to searchSign inGet full accessBBS-Bioactive Bone Substitutes Oyj
OYJBankruptY-tunnus 0866451-4Kiviharjunlenkki 6Research and experimental development on natural sciences and engineering · NACE 7210Est. 19913 employees
Revenue 2023
EUR 0
EBITDA margin
—
-11% vs 2022
Equity ratio
48.1%
Financial strength
Net profit 2023
EUR -3,5M
-11% vs 2022
| Revenue | EUR 0 | — |
| EBITDA | EUR -3,1M | -11% |
| Net profit | EUR -3,5M | -11% |
| Total assets | EUR 10,6M | -2% |
| Equity | EUR 5,1M | +1% |
| Employees | 3 | — |
Legal name
BBS-Bioactive Bone Substitutes Oyj
Y-tunnus number
0866451-4
Legal form
Julkinen osakeyhtiö
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6. helmikuuta 1991
Share capital
EUR 80 000
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsen ja toimitusjohtaja yhdessä sekä hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on harjoittaa lääketieteellistä ja hammaslääketieteellistä tutkimus- ja hoitotoimintaa sekä ylläpitää tutkimus- ja hoitolaitosta, välittää tähän toimintaan liittyviä palveluja, tuoda maahan, ostaa, myydä, vuokrata ja valmistaa tämän alan toiminnassa tarpeellisia koneita, laitteita, välineitä ja lääkeaineita. Lääketieteellinen toiminta tekoluun kaupallistamiseksi sekä harjoittaa liiketoimintaa tekoluulla sekä valmistusoikeuksilla.
Address
Kiviharjunlenkki 6
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −665 | −795 | −1 199 | −1 315 | −1 245 |
| EBITDA | −1 338 | −2 468 | −2 370 | −2 834 | −3 150 |
| Depreciation & amort. | −183 | −175 | −196 | −192 | −217 |
| EBIT | −1 521 | −2 644 | −2 566 | −3 026 | −3 367 |
| Net financials | −76 | −62 | −179 | −122 | −117 |
| Profit before tax | −1 597 | −2 706 | −2 745 | −3 148 | −3 484 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −1 597 | −2 706 | −2 745 | −3 148 | −3 484 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 9 909 | 12 760 | 10 663 | 10 849 | 10 613 |
| Equity | 3 702 | 6 735 | 4 308 | 5 066 | 5 108 |
| Long-term debt | 4 790 | 5 368 | 4 849 | 4 155 | 4 128 |
| Short-term debt | 1 417 | 656 | 1 505 | 1 629 | 1 377 |
| Total debt | 6 206 | 6 024 | 6 355 | 5 783 | 5 505 |
EBITDA margin
-314958300.0%
This company
15.8%
Market median
-1993407062% vs market
20192023
Equity ratio
48.1%
This company
38.2%
Market median
+26% vs market
20192023
Return on equity
-68.2%
This company
18.4%
Market median
-471% vs market
20192023
Net profit margin
-348361500.0%
This company
8.1%
Market median
-4300759359% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
1.08×
This company
0.62×
Market median
-74% vs market
20192023
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JH Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (4) | ||
IM Chief Executive Officer | Chief Executive Officer | 2019 – 2023 |
MJ Deputy auditor | Deputy auditor | 2020 – 2021 |
MJ Audit | Audit | 2017 – 2020 |
JP | Audit | 2020 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2024 | |
| Board of Directors | 2023 | |
| Chairperson | 2023 | |
| Board of Directors | 2020 | |
| Board of Directors | 2021 | |
| Former (4) | ||
| Board of Directors | 2018 – 2020 | |
| Board of Directors | 2018 – 2020 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
BBS-Bioactive Bone Substitutes Oyj 
Bio Bones OyBoard members of BBS-Bioactive Bone Substitutes Oyj also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ilkka Martti Olavi Kangasniemi | Chief Executive Officer | 0 companies |
| Milla Johanna Karjalainen | Deputy auditor | 0 companies |
| Markku Juhani Rönkkö | Audit | 0 companies |
| Jari Petteri Karppinen | Audit | 0 companies |
| Juliusz Henrik Tadeusz Rakowski | Chief Executive Officer | 0 companies |
| Gregor Heinrich Siebert | Board of Directors | 0 companies |
| Auvo Antero Juhani Kaikkonen | Board of Directors | 0 companies |
| Hannu Olavi Säynäjäkangas | Board of Directors | 0 companies |
| Tomi Juhani Numminen | Board of Directors | 0 companies |
| Jarmo Olavi Halonen | Board of Directors | 0 companies |
| Pekka Kalevi Aleksanteri Jalovaara | Chairperson | 0 companies |
| Seppo Juhani Nevalainen | Board of Directors | 0 companies |
| Ahti Petteri Paananen | Board of Directors | 0 companies |
| Kirk Patrick Andriano | Board of Directors | 0 companies |